KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Treasury Shares: 2010-2025

Historic Treasury Shares for Nektar Therapeutics (NKTR) over the last 1 years, with Jun 2025 value amounting to $552,307.

  • Nektar Therapeutics' Treasury Shares changed negligibly% to $552,307 in Q2 2025 from the same period last year, while for Jun 2025 it was $552,307, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $552,307 for FY2024, which is N/A change from last year.
  • Nektar Therapeutics' Treasury Shares amounted to $3.0 million in Q2 2025, which was down 0.00% from $3.0 million recorded in Q1 2025.
  • Nektar Therapeutics' Treasury Shares' 5-year high stood at $9.9 million during Q4 2021, with a 5-year trough of $552,307 in Q1 2024.
  • Moreover, its 2-year median value for Treasury Shares was $3.0 million (2025), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Treasury Shares surged by 39.98% in 2021, and later fell by 6.22% in 2022.
  • Quarterly analysis of 2 years shows Nektar Therapeutics' Treasury Shares stood at $3.0 million in 2024, then remained steady at $3.0 million in 2025.
  • Its Treasury Shares was $552,307 in Q2 2025, compared to $552,307 in Q1 2025 and $552,307 in Q4 2024.